Literature DB >> 18541193

Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.

Daniel Weisdorf1, Stephen Spellman, Michael Haagenson, Mary Horowitz, Stephanie Lee, Claudio Anasetti, Michelle Setterholm, Rebecca Drexler, Martin Maiers, Roberta King, Dennis Confer, John Klein.   

Abstract

The best unrelated donors (URD) for hematopoietic cell transplantation (HCT) are alleles matched at HLA-A, -B, -C, and DRB1. Earlier studies mostly used incomplete or lower resolution HLA typing for analysis of transplant outcome. To understand the impact of incomplete HLA characterization, we analyzed 14,797 URD HCT (1995-2006) using multivariable regression modeling adjusting for factors affecting survival. Of 21 matching cohorts, we identified 3 groups with significantly different outcomes. Well-matched cases had either no identified HLA mismatch and informative data at 4 loci or allele matching at HLA-A, -B, and -DRB1 (n = 7477, 50% of the population). Partially matched pairs had a defined, single-locus mismatch and/or missing HLA data (n = 4962, 34%). Mismatched cases had > or =2 allele or antigen mismatches (n = 2358, 16%). Multivariate adjusted 5-year survival estimates were: well-matched: 54.1 (95% confidence interval), 52.9-55.4), partially matched: 43.7 (42.3-45.2), and mismatched: 33.4 (32.5-36.5), P < .001. A better matched donor yielded 10%-11% better 5-year survival. Importantly, intermediate resolution -A, -B, and -DRB1 alleles matched "6/6 antigen matched" HCT had survival outcomes within the partially matched cohort. We suggest that these proposed HLA subgroupings be used when complete HLA typing is not available. This improved categorization of HLA matching status allows adjustment for donor-recipient HLA compatibility, and can standardize interpretations of prior URD HCT experience.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541193      PMCID: PMC2668157          DOI: 10.1016/j.bbmt.2008.04.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

1.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.

Authors:  E W Petersdorf; J A Hansen; P J Martin; A Woolfrey; M Malkki; T Gooley; B Storer; E Mickelson; A Smith; C Anasetti
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

2.  Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors.

Authors:  E W Petersdorf; G M Longton; C Anasetti; E M Mickelson; S K McKinney; A G Smith; P J Martin; J A Hansen
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

3.  Definition of HLA-DQ as a transplantation antigen.

Authors:  E W Petersdorf; G M Longton; C Anasetti; E M Mickelson; A G Smith; P J Martin; J A Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Authors:  Yasuo Morishima; Takehiko Sasazuki; Hidetoshi Inoko; Takeo Juji; Tatsuya Akaza; Ken Yamamoto; Yoshihide Ishikawa; Shunichi Kato; Hiroshi Sao; Hisashi Sakamaki; Keisei Kawa; Nobuyuki Hamajima; Shigetaka Asano; Yoshihisa Kodera
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

5.  Limits of HLA mismatching in unrelated hematopoietic cell transplantation.

Authors:  Effie W Petersdorf; Claudio Anasetti; Paul J Martin; Ted Gooley; Jerald Radich; Mari Malkki; Ann Woolfrey; Anajane Smith; Eric Mickelson; John A Hansen
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

7.  The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation.

Authors:  E W Petersdorf; A G Smith; E M Mickelson; G M Longton; C Anasetti; S Y Choo; P J Martin; J A Hansen
Journal:  Blood       Date:  1993-04-01       Impact factor: 22.113

8.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

Authors:  E W Petersdorf; T A Gooley; C Anasetti; P J Martin; A G Smith; E M Mickelson; A E Woolfrey; J A Hansen
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

10.  The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation.

Authors:  E W Petersdorf; G M Longton; C Anasetti; P J Martin; E M Mickelson; A G Smith; J A Hansen
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  124 in total

1.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

Authors:  Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmund K Waller; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

3.  Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.

Authors:  B Thyagarajan; S Jackson; S Basu; P Jacobson; M D Gross; D J Weisdorf; M Arora
Journal:  Int J Immunogenet       Date:  2012-05-30       Impact factor: 1.466

4.  Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Saurabh Chhabra; Kwang Woo Ahn; Zhen-Huan Hu; Sandeep Jain; Amer Assal; Jan Cerny; Edward A Copelan; Andrew Daly; Zachariah DeFilipp; Shahinaz M Gadalla; Robert Peter Gale; Siddhartha Ganguly; Betty K Hamilton; Gerhard Carl Hildebrandt; Jack W Hsu; Yoshihiro Inamoto; Abraham S Kanate; H Jean Khoury; Hillard M Lazarus; Mark R Litzow; Sunita Nathan; Richard F Olsson; Attaphol Pawarode; Olle Ringden; Jacob M Rowe; Ayman Saad; Bipin N Savani; Harry C Schouten; Sachiko Seo; Nirav N Shah; Melhem Solh; Robert K Stuart; Celalettin Ustun; Ann E Woolfrey; Jean A Yared; Edwin P Alyea; Matt E Kalaycio; Uday Popat; Ronald M Sobecks; Wael Saber
Journal:  Blood Adv       Date:  2018-11-13

5.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

Authors:  Mukta Arora; John P Klein; Daniel J Weisdorf; Anna Hassebroek; Mary E D Flowers; Corey S Cutler; Alvaro Urbano-Ispizua; Joseph H Antin; Brian J Bolwell; Michael Boyiadzis; Jean-Yves Cahn; Mitchell S Cairo; Luis Isola; David A Jacobsohn; Madan Jagasia; Thomas R Klumpp; Stephanie J Lee; Effie W Petersdorf; Stella Santarone; Robert Peter Gale; Harry C Schouten; Stephen Spellman; John R Wingard; Mary M Horowitz; Steven Z Pavletic
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

6.  Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match.

Authors:  Jason Dehn; Mukta Arora; Stephen Spellman; Michelle Setterholm; Mary Horowitz; Dennis Confer; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

7.  Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Authors:  Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Ginna G Laport; Silvia Montoto; David G Maloney; Hillard M Lazarus
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-01       Impact factor: 5.742

8.  Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.

Authors:  Genovefa A Papanicolaou; Celalettin Ustun; Jo-Anne H Young; Min Chen; Soyoung Kim; Kwang Woo Ahn; Krishna Komanduri; Caroline Lindemans; Jeffery J Auletta; Marcie L Riches
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

9.  The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.

Authors:  Sarah Schmidt; Ying Liu; Zhen-Huan Hu; Kirsten M Williams; Hillard M Lazarus; Ravi Vij; Mohamed A Kharfan-Dabaja; Guillermo Ortí; Peter H Wiernik; Daniel Weisdorf; Rammurti T Kamble; Roger Herzig; Baldeep Wirk; Jan Cerny; Ulrike Bacher; Naeem A Chaudhri; Sunita Nathan; Nosha Farhadfar; Mahmoud Aljurf; Usama Gergis; Jeffrey Szer; Sachiko Seo; Jack W Hsu; Richard F Olsson; Dipnarine Maharaj; Biju George; Gerhard C Hildebrandt; Vaibhav Agrawal; Taiga Nishihori; Hisham Abdel-Azim; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Jennifer Holter Chakrabarty; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-14       Impact factor: 5.742

10.  Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Susan F Leitman; Paolo Anderlini; John P Klein; Mary M Horowitz; John P Miller; Roberta J King; Dennis L Confer
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.